Free Trial
NASDAQ:TCBP

TC Biopharm (TCBP) Stock Price, News & Analysis

TC Biopharm logo
$0.68 -0.86 (-55.78%)
Closing price 03/21/2025
Extended Trading
$0.68 0.00 (0.00%)
As of 03/21/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About TC Biopharm Stock (NASDAQ:TCBP)

Key Stats

Today's Range
$0.50
$1.54
50-Day Range
$0.68
$0.68
52-Week Range
$0.50
$160.00
Volume
5.33 million shs
Average Volume
165,016 shs
Market Capitalization
$279.21 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.00
Consensus Rating
Buy

Company Overview

Receive TCBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TC Biopharm and its competitors with MarketBeat's FREE daily newsletter.

TCBP Stock News Headlines

TC BioPharm Holdings PLC (TCBPY)
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
TC Biopharm announces transition to OTC Markets from Nasdaq
See More Headlines

TCBP Stock Analysis - Frequently Asked Questions

TC Biopharm's stock was trading at $10.32 on January 1st, 2025. Since then, TCBP stock has decreased by 93.4% and is now trading at $0.6810.

TC Biopharm's stock reverse split on Monday, February 10th 2025.The 1-20 reverse split was announced on Wednesday, February 5th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

TC Biopharm (TCBP) raised $17 million in an initial public offering on Friday, February 11th 2022. The company issued 4,100,000 shares at $4.25 per share. EF Hutton served as the underwriter for the IPO.

Shares of TCBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that TC Biopharm investors own include Johnson & Johnson (JNJ), Procter & Gamble (PG), Taiwan Semiconductor Manufacturing (TSM), Exxon Mobil (XOM), International Business Machines (IBM), NextEra Energy (NEE) and Union Pacific (UNP).

Company Calendar

Today
7/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TCBP
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$48.00
High Stock Price Target
$48.00
Low Stock Price Target
$48.00
Potential Upside/Downside
+6,948.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.76 million
Price / Cash Flow
N/A
Book Value
$519.58 per share
Price / Book
0.00

Miscellaneous

Free Float
28,000
Market Cap
$279.21 thousand
Optionable
Not Optionable
Beta
0.01
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:TCBP) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners